QR Code (код быстрого отклика)

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Abstract Background Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA repair pathway have been observed in ~ 10% of uLMS cases, with reports of...

Полное описание

Сохранить в:
Главные авторы: Genevieve Dall, Cassandra J. Vandenberg, Ksenija Nesic, Gayanie Ratnayake, Wenying Zhu, Joseph H. A. Vissers, Justin Bedő, Jocelyn Penington, Matthew J. Wakefield, Damien Kee, Amandine Carmagnac, Ratana Lim, Kristy Shield-Artin, Briony Milesi, Amanda Lobley, Elizabeth L. Kyran, Emily O’Grady, Joshua Tram, Warren Zhou, Devindee Nugawela, Kym Pham Stewart, Reece Caldwell, Lia Papadopoulos, Ashley P. Ng, Alexander Dobrovic, Stephen B. Fox, Orla McNally, Jeremy D. Power, Tarek Meniawy, Teng Han Tan, Ian M. Collins, Oliver Klein, Stephen Barnett, Inger Olesen, Anne Hamilton, Oliver Hofmann, Sean Grimmond, Anthony T. Papenfuss, Clare L. Scott, Holly E. Barker
Формат: Artigo
Язык:Inglês
Опубликовано: BMC 2023-05-01
Серии:Journal of Experimental & Clinical Cancer Research
Предметы:
Uterine leiomyosarcoma
Homologous recombination deficiency
PARP inhibitors
Rare cancers
Patient-derived xenografts
Online-ссылка:https://doi.org/10.1186/s13046-023-02687-0
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы